Breast Cancer brain metastases Responding To Primary Systemic ...
In summary, to our best knowledge, this is the first report on breast cancer brain metastases responding to primary systemic therapy with T-DM1. ... Doc Viewer
HER2-Positive Breast Cancer - Research To Practice
Manage brain metastases, which occur in approximately 50% of patients with metastatic HER2-positive disease. In addition A trial of TDM1 after surgery for breast cancer (KATHERINE). Available at: http://www.cancerresearchuk. ... Read Document
Trastuzumab Emtansine (T-DM1) Versus Lapatinib Plus
Brain metastases and improved survival after the development of brain metastases [4, 5, 19–21]. Although trastuzumab is gen-erally believed to be too large to cross the blood–brain barrier, a recent positron emission tomography imaging study using 89Zr- ... Get Document
A Phase 1b Study Of ONT-380, An Oral HER2-specific Inhibitor ...
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab (T-DM1), in HER2+ metastatic breast cancer (MBC) progressive metastases after prior whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) allowed ... Get Content Here
Long-term Survival After Lapatinib Rechallenge In Isolated ...
Considered as effective treatment option in brain metastases from HER2-positive breast cancer (3, 4). (pertuzumab, TDM1 etc.). Informed Consent: Written informed consent was obtained from pa- A phase II study of lapatinib for brain metastases in patients with ... Fetch Full Source
Safety And Efficacy Of The Combination Of T-DM1 With ...
Keywords: breast cancer, HER2-positive, TDM1, radiotherapy. Case Report 2 www.ecancer.org ecancer 2015, 9:586 7. Devriendt D, Levivier M and Hilderbrand J (2006) Treatment of brain metastases from breast cancer Breast Cancer Mol Med 505–523 DOI: 10.1007/978-3-540-28266-2 8. ... Get Content Here
Safety And Efficacy Of Lapatinib Plus Trastuzumab Or ...
Prior treatment with trastuzumab-DM1 (TDM1) is allowed (T-DM1 represents one line of anti-HER2 and one line of chemotherapy). attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. ... View Document
HERMIONE: A Phase 2, Randomized, Open Label Trial Comparing ...
And demonstrates deposition in difficult to treat regions such as brain and bone metastasis (Miller et al., SABCS 2014, Poster P4-15-04) ELIGIBILITY STATISTICAL METHODS new CNS metastases • To estimate the resources for hospitalization and/or ... Document Viewer
Innovave(Trial(Concepts(for( Brain(Metastases(
Innovave(Trial(Concepts(for(Brain(Metastases(Minesh(P(Mehta,(MD,(FASTRO(Professor,(University(of(Maryland(Historic(Trial(Design Brain penetrang$ an4Her2$Rx$ LapCapor TDM1$ 1° end pt: 6 month distant brain relapse rate . Alternave(Design(Op&ons ... Return Doc
BREAST CANCER BRAIN METASTASIS TARGETED THERAPIES - GEINO
BREAST CANCER BRAIN METASTASIS TARGETED THERAPIES • BACKGROUND • SYSTEMIC TREATMENT – HER2 TARGETED AGENTS – ANTIANGIOGENIC THERAPIES growing recognition that patients with brain metastases should be included in clinical trials Wen PY, J Clin Oncol 2011. PROSPECTIVE CLINICAL TRIALS ... Fetch Doc
Trastuzumab Emtansine - Wikipedia, The Free Encyclopedia
Trastuzumab emtansine (INN; [1] [2] in the United States, ado-trastuzumab emtansine, trade name Kadcyla) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent DM1. ... Read Article
A Phase 1b Study Of ONT-380, An Oral HER2-Specific Inhibitor ...
• Patients with brain metastases eligible, including untreated metastases or metastases progressive after prior treatment Study Design ... Get Content Here
Cancer With Previously Treated HER2-Positive Metastatic ...
With Previously Treated HER2-Positive Metastatic Breast Cancer Presentation discussed in this issue: Krop I et al. A Phase II study of trastuzumab-DM1 brain metastases within 2 months of first dose Source: Krop 1 et al. SABCS 2009;Abstract 5090. T-DMI 3.6 mg/kg IV q3wk ... Fetch Full Source
Activity Of T-DM1 In Her2-positive Breast Cancer brain metastases
Activity of T-DM1 in Her2-positive breast cancer brain metastases Prior Her2 targeted therapy before initiation of TDM1 Trastuzumab Yes 10 100.0 No 0 0.0 Lapatinib Yes 6 60.0 No 4 40.0 Pertuzumab Yes 3 30.0 No 7 70.0 Time to development of BM from diagnosis of BC, ... Document Viewer
Metastatic Breast Cancer 201
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 . Overview breast cancer with brain metastases A 2-arm study of TDM1 vs. TPC ... Retrieve Content
Management Of Patients With Her2+ve Brain metastases
Management of Patients with Her2+ve Brain metastases • Her2+ve patients 15% of all breast cancer • Even with adjuvant trastuzumab 10-15% relapse ... Read Document
Management Of Patients With Her2+ve Brain metastases
Management of Patients with Her2+ve Brain metastases. Presentation at diagnosis with brain metastases +/- systemic disease Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: RCT ... Fetch Content
Synopsis TDM1 Feb 12 - Cancertrials.be
Preoperative setting, 3 antiHER2 strategies, namely trastuzumab, lapatinib or their combination given alone for 6 weeks and then for 3 months with weekly paclitaxel prior to surgery. ... Doc Retrieval
No comments:
Post a Comment